Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

OFEV slows disease, lowers risk of death in IPF
April 2016
EDIT CONNECT

SHARING OPTIONS:

RIDGEFIELD, Conn.—Boehringer Ingelheim recently announced that analysis of the data from the Phase 2 TOMORROW trials and Phase 3 INPULSIS trials showed that OFEV (nintedanib), a small-molecule tyrosine kinase inhibitor for patients with idiopathic pulmonary fibrosis (IPF), reduces the risk of acute exacerbations by roughly 50 percent in IPF patients. OFEV was also shown to slow disease progression by approximately 50 percent across the range of patient types in clinical trials. Compared to placebo, OFEV reduced the risk of an acute exacerbation as reported by treating physicians by 47 percent. Over the year the studies ran, patients taking OFEV demonstrated a 30-percent reduction in the risk of dying from any cause, and a 38-percent reduction in the risk of dying due to an exacerbation or other respiratory cause, compared to placebo.
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.